Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Mylotarg Safety Profile Supports Use In Patients 60 - Advisory Cmte.

Executive Summary

Wyeth's treatment for relapsed acute myeloid leukemia patients Mylotarg was recommended for accelerated approval in patients 60 years and older by FDA's Oncologic Drugs Advisory Committee March 17.

You may also be interested in...



Mylotarg Phase IV Study In AML To Examine Combo Therapy For First-line Use

Wyeth-Ayerst is planning a Phase IV study to evaluate Mylotarg in combination therapy for the treatment of patients recently diagnosed with CD33 positive acute myeloid leukemia, the company said.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel